One of the most consequential fights inside cannabis is whether the answer to intoxicating hemp is prohibition or regulation. Aaron Smith, co-founder and former CEO of the National Cannabis Industry Association, has argued that licensed marijuana businesses pushing Congress toward a sweeping hemp-THC ban are choosing the wrong strategy. I agree with the direction of that argument, with one important condition: parity has to mean serious consumer-protection rules, not a regulatory vacuum.
What is the argument for parity?
Delta-9 THC is the same molecule regardless of whether the legal system classifies the source plant as hemp or marijuana. That makes source alone a poor basis for deciding whether an intoxicating product is safe, unsafe or appropriately regulated.
But molecular parity does not mean every product presents the same risk. Dose, route of administration, formulation, contaminants, conversion chemistry, packaging, marketing and retail environment all matter. A sensible federal framework should regulate those characteristics directly rather than pretending the plant’s legal category answers every safety question.
Where does the prohibition approach fall short?
A broad ban can collapse very different products into one category: naturally derived delta-9 THC, THCa flower, low-dose beverages and edibles, and cannabinoids created or modified through chemical conversion. Those products deserve evidence-based rules appropriate to their actual characteristics.
The licensed marijuana industry’s frustration is understandable. State-regulated operators carry testing requirements, taxes, licensing costs, track-and-trace obligations and other compliance expenses while some hemp-derived intoxicating products have reached consumers under lighter rules. That is a genuine competitive imbalance. The answer should be to close the regulatory gap, not automatically recreate prohibition around the competing category.
What would smarter federal regulation look like?
Start with outcomes: adults know what they are buying, minors cannot legally purchase it, products are tested for relevant contaminants, labels accurately state cannabinoid content and serving size, packaging does not mimic products marketed to children, and regulators can identify and penalize bad actors.
From there, Congress and regulators can distinguish among product types. Low-dose beverages do not have to be regulated identically to inhalable concentrates. Chemically converted cannabinoids do not have to be treated identically to naturally occurring delta-9 THC. Higher-potency products can carry different retail restrictions than lower-dose products without pretending the underlying molecule changes when it crosses a statutory line.
Why does the political strategy matter?
Cannabis reform has spent decades arguing that prohibition is a poor substitute for sensible regulation. Licensed operators should be careful about abandoning that principle when the competitor happens to come from the hemp side of the market.
That does not require defending unsafe products or an unregulated market. It means making the stronger argument: intoxicating cannabinoid products should operate under enforceable rules proportionate to their risks, and businesses selling equivalent products should not gain an artificial advantage merely because Congress drew an awkward botanical line in 2018.
The operator pressure behind this fight is real. See why Ohio hemp operators say state rules favor big marijuana, the newer Ohio hemp-ban analysis, and the broader Cannabis Business and Markets collection.
Frequently Asked Questions
- Is hemp-derived delta-9 THC chemically different from marijuana-derived delta-9 THC? No. Delta-9 THC is the same molecule. Product safety and regulatory questions can still differ because dose, formulation, contaminants, manufacturing and route of administration matter.
- Does opposing a blanket ban mean supporting an unregulated hemp market? No. A parity framework can include age restrictions, testing, accurate labels, dosage standards, packaging rules and meaningful enforcement.
- Should every intoxicating cannabinoid product have identical rules? Not necessarily. Regulation can distinguish products based on evidence about potency, route, manufacturing and risk rather than relying only on whether the source plant is legally hemp or marijuana.
- Why are licensed cannabis operators frustrated? They often carry significant state compliance costs while competing against intoxicating hemp products sold under lighter or inconsistent rules.
Source and argument being discussed: Marijuana Moment, Aaron Smith op-ed on hemp THC policy.